Trial Profile
Dose finding study of the combination chemotherapy consisting of irinotecan hydrochloride and pegylated liposomal doxorubicin combination therapy in patients with recurrent ovarian cancer (Phase I trial).
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Irinotecan (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 11 May 2012 Status changed from active, no longer recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 13 Mar 2012 Status changed from suspended to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 23 Dec 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.